the first point you made is important. A lot of take over stats show a premium to SP. but as compared to ATH they can be heavily discounted eg VLA and RAP down from $0.38c in October 2019.
I think it is difficult for BOD to be objective, if they see a sale as the only way for them to exit. If in the millions they possibly don’t mind taking a hair cut but that doesn’t help the little guy who is in the red!
Having competition is key, if Pzifer is a last ditch effort then rejecting it could risk the one and only deal. Not a good position to be in. Pzifer holds all the cards in this instance a market is crap so they are trying to scoop a bargain.
That’s why being under the radar ain’t such a bad thing atm. There needs to clearly be an on the radar strategy / campaign at some point to rollout to market!
not in RAP but will be interesting to see the outcome.
Industry news, page-583
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.030(2.11%) |
Mkt cap ! $247.1M | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.45 | $1.40 | $163.8K | 115.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 31396 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |